Brief: Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (Camoteskimab) To Apollo Therapeutics

Avalo Therapeutics

01/08/2022 13:02

Aug 1 (Reuters) - Avalo Therapeutics Inc  AVTX.O :
    * AVALO THERAPEUTICS TRANSFERS ANTI-IL-18 ANTIBODY, AVTX-007
(CAMOTESKIMAB) TO APOLLO THERAPEUTICS
    * AVALO THERAPEUTICS INC - AVALO TO RECEIVE AN APPROXIMATELY
$15
MILLION UPFRONT PAYMENT, UP TO $74 MILLION IN MILESTONE PAYMENTS
    * AVALO THERAPEUTICS INC - APOLLO TO LEAD CONTINUED CLINICAL
DEVELOPMENT OF AVTX-007, CURRENTLY IN PHASE 1B

Source text for Eikon:  ID:nGNX2BgK6s 
Further company coverage:  AVTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))